Kiora Pharmaceuticals, Inc.: Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
Salt Lake City, Utah--(Newsfile Corp. - December 14, 2021) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced topline data from its vehicle-controlled, randomized safety
Source: finanznachrichten.de